Form 4: Kaufman Descendants Trust Completes Share Sales Under 10b5-1 Plan

The Kaufman Descendants Trust completed a series of share sales of Agilysys Inc. stock under a pre-arranged 10b5-1 trading plan.

Summary

• The Kaufman 2012 Descendants Trust, with David N. Smith as trustee, executed multiple sales of Agilysys Inc. common stock.
• These transactions occurred between January 22, 2025 and January 24, 2025.
• A total of 22,692 shares were sold at prices ranging from $93.10 to $100.17 per share.
• The sales were conducted under a Rule 10b5-1 trading plan established on September 10, 2024.
• The trading plan has now been completed, and no further sales will occur under this plan.
• Michael Kaufman, a director of Agilysys Inc., is a beneficiary of the trust but disclaims beneficial ownership of the shares held by the trust.
• Michael Kaufman also directly owns 9,580 shares and may be deemed to indirectly own 1,192,730 shares through MAK Capital Fund LP, although he disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 6

Explanation: The document is neutral in tone, reporting routine insider transactions. The completion of the 10b5-1 plan is a positive, but the sales themselves could be seen as slightly negative.

Positives

• The completion of the 10b5-1 trading plan provides clarity on future share sales from the trust.
• The disclosure of the transactions provides transparency to the market.

Negatives

• The sales by the trust may exert some downward pressure on the stock price.

Risks

• The market may react negatively to the continued selling of shares by insiders, even if pre-planned.
• There is a risk of further sales by Michael Kaufman or related entities in the future.

Future Outlook

The Rule 10b5-1 Trading Plan has been completed, and there will be no further sales of shares under this plan.

Management Comments

• Michael Kaufman disclaims beneficial ownership of the shares held by the Trust.
• Michael Kaufman has disclaimed beneficial ownership of shares held by MAK Capital Fund LP, except to the extent of its pecuniary interest therein.

Industry Context

This filing is a routine disclosure of insider transactions and is common for publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to manage their stock sales in a compliant manner.
• The reported transactions are similar to those seen in other Form 4 filings for publicly traded companies.
• The volume of shares sold is not unusual for a trust associated with a director.

Stakeholder Impact

• Shareholders may be concerned about the selling activity, but the pre-planned nature of the sales mitigates this concern.
• The completion of the 10b5-1 plan provides clarity for investors.

Key Dates

Keywords

Agilysys Inc, Kaufman Descendants Trust, Rule 10b5-1, share sales, insider trading, David N. Smith, Michael Kaufman, stock transaction